The discovery of EGFR tyrosine kinase inhibitor (EGFR‐TKI) is an important milestone in the development of tumor‐targeted therapy in NSCLC and greatly improves the outcomes of NSCLC patients. This evidence concerns the gene EGFR and neoplasm.